search
Back to results

RCE With FMT in the Treatment of Childhood Constipation

Primary Purpose

Fecal Microbiota Transplantation, Constipation - Functional

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Fecal supernatant
Placebo
Sponsored by
Shengjing Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fecal Microbiota Transplantation

Eligibility Criteria

4 Years - 14 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  • 4-14 years old;
  • Roman IV criteria for childhood constipation;
  • After a course of PEG and a course of Chinese medicine treatment was ineffective;
  • Barium enema showing fecal impaction.

Exclusion criteria:

  • Congenital and/or acquired intestinal diseases, such as congenital megacolon, intestinal stenosis, polyps, Crohn's disease, tuberculosis, inflammation, and tumors;
  • Anorectal diseases, such as anal atresia, fistula, abscess, and tumor;
  • Neurological diseases, such as brain and spinal cord diseases;
  • genetic metabolic diseases;
  • psychosocial and behavioral diseases;
  • other systemic diseases;
  • Refused to participate in.

Sites / Locations

  • Shengjing HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Fecal supernatant

non-Fecal supernatant

Arm Description

Fecal supernatant is used for treatment of childhood Constipation

Placebo is used for treatment of childhood Constipation

Outcomes

Primary Outcome Measures

improvement of CSBMs (sub/week) from baseline
the frequency of defecation without drugs or other auxiliary methods
improvement of CSBMs (sub/week) from baseline
the frequency of defecation without drugs or other auxiliary methods
improvement of CSBMs (sub/week) from baseline
the frequency of defecation without drugs or other auxiliary methods
Satisfaction with bowel function
Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no).
Satisfaction with bowel function
Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no).
Satisfaction with bowel function
Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no).

Secondary Outcome Measures

Bowel movements
the frequency of bowel movements per week
Bowel movements
the frequency of bowel movements per week
Bowel movements
the frequency of bowel movements per week
Painful or hard bowel movements
The feelings of children during defecation
Painful or hard bowel movements
The feelings of children during defecation
Painful or hard bowel movements
The feelings of children during defecation
Large diameter or scybalous stools
appearance and wetness of stool
Large diameter or scybalous stools
appearance and wetness of stool
Large diameter or scybalous stools
appearance and wetness of stool
Excessive volitional stool retention
The number of children who intentionally control or reduce the frequency of defecation
Excessive volitional stool retention
The number of children who intentionally control or reduce the frequency of defecation
Excessive volitional stool retention
The number of children who intentionally control or reduce the frequency of defecation
Encopresis
the frequency of fecal incontinence
Encopresis
the frequency of fecal incontinence
Encopresis
the frequency of fecal incontinence

Full Information

First Posted
August 26, 2021
Last Updated
December 13, 2021
Sponsor
Shengjing Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05035784
Brief Title
RCE With FMT in the Treatment of Childhood Constipation
Official Title
Retrograde Colonic Enema With Fecal Microbiota Transplantation vs Retrograde Colonic Enema Only in the Treatment of Childhood Constipation
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Unknown status
Study Start Date
August 3, 2019 (Actual)
Primary Completion Date
October 3, 2021 (Actual)
Study Completion Date
March 3, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shengjing Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
Constipation is the most common complaint in childhood gastrointestinal disease, affecting an estimated 20% of the global children.The treatment strategies consist of diet control, behavioral intervention and oral and sometimes rectal laxatives. Given higher success rate and fewer side effects, the laxative PEG3350 has been considered the first choice in childhood constipation.However, effectiveness of PEG 3350 laxative is not lasting, and the use of PEG increases the risk of fecal incontinence. Additional treatment interventions are still necessary.Enema can act directly on the rectum and distal colon to quickly relieve symptoms of fecal impaction which is considered one of main source of intractable constipation. Children with fecal impaction who received enema had fewer fecal incontinence and diarrhea than children who received PEG. There have been lots of evidence that enema is effective in fecal impaction in children with functional constipation.But there are still cases of recurrences noted after enema. Fecal bacteria transplantation (FMT) is a new treatment method emerging in recent years, which is widely used in the treatment of functional gastrointestinal diseases. FMT has been proved to play a very prominent role in correcting intestinal flora disorders. By transplanting exogenous flora into the intestinal tract of patients, FMT can inhibit bacterial reproduction, regulate intestinal environment and cascade the body immunity, so as to achieve the therapeutic effect of disease. Retrograde colonic enema with FMT, an new method, provides the possibility for the treatment of childhood constipation. However, there is still a lack of evidence-based support for the treatment of childhood constipation by retrograde colonic enema with FMT. Therefore, we designed a randomized, controlled, double-blind clinical trial to confirm the efficacy and safety of retrograde colonic enema with FMT in the treatment of childhood constipation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fecal Microbiota Transplantation, Constipation - Functional

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
110 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Fecal supernatant
Arm Type
Active Comparator
Arm Description
Fecal supernatant is used for treatment of childhood Constipation
Arm Title
non-Fecal supernatant
Arm Type
Placebo Comparator
Arm Description
Placebo is used for treatment of childhood Constipation
Intervention Type
Drug
Intervention Name(s)
Fecal supernatant
Intervention Description
Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.
Primary Outcome Measure Information:
Title
improvement of CSBMs (sub/week) from baseline
Description
the frequency of defecation without drugs or other auxiliary methods
Time Frame
Baseline
Title
improvement of CSBMs (sub/week) from baseline
Description
the frequency of defecation without drugs or other auxiliary methods
Time Frame
at the end of 4-weeks FMT treatment
Title
improvement of CSBMs (sub/week) from baseline
Description
the frequency of defecation without drugs or other auxiliary methods
Time Frame
at the end of 12 weeks follow-up
Title
Satisfaction with bowel function
Description
Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no).
Time Frame
Baseline
Title
Satisfaction with bowel function
Description
Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no).
Time Frame
at the end of 4-weeks FMT treatment
Title
Satisfaction with bowel function
Description
Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no).
Time Frame
at the end of 12 weeks follow-up
Secondary Outcome Measure Information:
Title
Bowel movements
Description
the frequency of bowel movements per week
Time Frame
Baseline
Title
Bowel movements
Description
the frequency of bowel movements per week
Time Frame
at the end of 4-weeks FMT treatment
Title
Bowel movements
Description
the frequency of bowel movements per week
Time Frame
at the end of 12 weeks follow-up
Title
Painful or hard bowel movements
Description
The feelings of children during defecation
Time Frame
Baseline
Title
Painful or hard bowel movements
Description
The feelings of children during defecation
Time Frame
at the end of 4-weeks FMT treatment
Title
Painful or hard bowel movements
Description
The feelings of children during defecation
Time Frame
at the end of 12 weeks follow-up
Title
Large diameter or scybalous stools
Description
appearance and wetness of stool
Time Frame
Baseline
Title
Large diameter or scybalous stools
Description
appearance and wetness of stool
Time Frame
at the end of 4-weeks FMT treatment
Title
Large diameter or scybalous stools
Description
appearance and wetness of stool
Time Frame
at the end of 12 weeks follow-up
Title
Excessive volitional stool retention
Description
The number of children who intentionally control or reduce the frequency of defecation
Time Frame
Baseline
Title
Excessive volitional stool retention
Description
The number of children who intentionally control or reduce the frequency of defecation
Time Frame
at the end of 4-weeks FMT treatment
Title
Excessive volitional stool retention
Description
The number of children who intentionally control or reduce the frequency of defecation
Time Frame
at the end of 12 weeks follow-up
Title
Encopresis
Description
the frequency of fecal incontinence
Time Frame
Baseline
Title
Encopresis
Description
the frequency of fecal incontinence
Time Frame
at the end of 4-weeks FMT treatment
Title
Encopresis
Description
the frequency of fecal incontinence
Time Frame
at the end of 12 weeks follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: 4-14 years old; Roman IV criteria for childhood constipation; After a course of PEG and a course of Chinese medicine treatment was ineffective; Barium enema showing fecal impaction. Exclusion criteria: Congenital and/or acquired intestinal diseases, such as congenital megacolon, intestinal stenosis, polyps, Crohn's disease, tuberculosis, inflammation, and tumors; Anorectal diseases, such as anal atresia, fistula, abscess, and tumor; Neurological diseases, such as brain and spinal cord diseases; genetic metabolic diseases; psychosocial and behavioral diseases; other systemic diseases; Refused to participate in.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shucheng ZHANG
Phone
86-24-96615-57911
Email
zhangshucheng76@126.com
Facility Information:
Facility Name
Shengjing Hospital
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110004
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shucheng ZHANG
Phone
86-24-96615-57911
Email
zhangshucheng76@126.com

12. IPD Sharing Statement

Citations:
PubMed Identifier
27529553
Citation
Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016 Aug 16;11(8):e0161174. doi: 10.1371/journal.pone.0161174. eCollection 2016.
Results Reference
background
PubMed Identifier
31169545
Citation
Gurram B, Sue PK. Fecal microbiota transplantation in children: current concepts. Curr Opin Pediatr. 2019 Oct;31(5):623-629. doi: 10.1097/MOP.0000000000000787.
Results Reference
background
PubMed Identifier
30908299
Citation
Xu D, Chen VL, Steiner CA, Berinstein JA, Eswaran S, Waljee AK, Higgins PDR, Owyang C. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019 Jul;114(7):1043-1050. doi: 10.14309/ajg.0000000000000198.
Results Reference
background
PubMed Identifier
26751143
Citation
Tian H, Ding C, Gong J, Ge X, McFarland LV, Gu L, Wei Y, Chen Q, Zhu W, Li J, Li N. Treatment of Slow Transit Constipation With Fecal Microbiota Transplantation: A Pilot Study. J Clin Gastroenterol. 2016 Nov/Dec;50(10):865-870. doi: 10.1097/MCG.0000000000000472.
Results Reference
background
PubMed Identifier
30809523
Citation
Ohkusa T, Koido S, Nishikawa Y, Sato N. Gut Microbiota and Chronic Constipation: A Review and Update. Front Med (Lausanne). 2019 Feb 12;6:19. doi: 10.3389/fmed.2019.00019. eCollection 2019.
Results Reference
background
PubMed Identifier
31665572
Citation
Kassam Z, Dubois N, Ramakrishna B, Ling K, Qazi T, Smith M, Kelly CR, Fischer M, Allegretti JR, Budree S, Panchal P, Kelly CP, Osman M. Donor Screening for Fecal Microbiota Transplantation. N Engl J Med. 2019 Nov 21;381(21):2070-2072. doi: 10.1056/NEJMc1913670. Epub 2019 Oct 30. No abstract available.
Results Reference
background
PubMed Identifier
22002980
Citation
Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011 Nov;53(10):994-1002. doi: 10.1093/cid/cir632.
Results Reference
background
PubMed Identifier
31690829
Citation
Vriesman MH, Koppen IJN, Camilleri M, Di Lorenzo C, Benninga MA. Management of functional constipation in children and adults. Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):21-39. doi: 10.1038/s41575-019-0222-y. Epub 2019 Nov 5.
Results Reference
background
PubMed Identifier
27688650
Citation
Clemente MG, Mandato C, Poeta M, Vajro P. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 2016 Sep 28;22(36):8078-93. doi: 10.3748/wjg.v22.i36.8078.
Results Reference
background
PubMed Identifier
28129018
Citation
Woodworth MH, Carpentieri C, Sitchenko KL, Kraft CS. Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. Gut Microbes. 2017 May 4;8(3):225-237. doi: 10.1080/19490976.2017.1286006. Epub 2017 Jan 27.
Results Reference
background
PubMed Identifier
28164849
Citation
Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am. 2017 Mar;46(1):171-185. doi: 10.1016/j.gtc.2016.09.012.
Results Reference
background
PubMed Identifier
29358877
Citation
Shen ZH, Zhu CX, Quan YS, Yang ZY, Wu S, Luo WW, Tan B, Wang XY. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018 Jan 7;24(1):5-14. doi: 10.3748/wjg.v24.i1.5.
Results Reference
background
PubMed Identifier
31639033
Citation
Dai M, Liu Y, Chen W, Buch H, Shan Y, Chang L, Bai Y, Shen C, Zhang X, Huo Y, Huang D, Yang Z, Hu Z, He X, Pan J, Hu L, Pan X, Wu X, Deng B, Li Z, Cui B, Zhang F. Rescue fecal microbiota transplantation for antibiotic-associated diarrhea in critically ill patients. Crit Care. 2019 Oct 21;23(1):324. doi: 10.1186/s13054-019-2604-5.
Results Reference
background

Learn more about this trial

RCE With FMT in the Treatment of Childhood Constipation

We'll reach out to this number within 24 hrs